INMED PHARMACEUTICALS INC. Cost of Revenue
INMED PHARMACEUTICALS INC. (INM) reported Cost of Revenue of $635.99 thousand for the 3-month period ending 2025-12-31, per its 10-Q filed 2026-02-11.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-07-02
- INMED PHARMACEUTICALS INC. cost of revenue for the quarter ending 2025-12-31 was $635.99K, a 2.28% decline year-over-year.
- INMED PHARMACEUTICALS INC. cost of revenue for the quarter ending 2025-09-30 was $716.96K, a 7.04% decline year-over-year.
- INMED PHARMACEUTICALS INC. cost of revenue for the quarter ending 2025-06-30 was $728.06K, a 10.89% decline year-over-year.
- INMED PHARMACEUTICALS INC. cost of revenue for the quarter ending 2025-03-31 was $1.09M, a 22.96% increase year-over-year.
- INMED PHARMACEUTICALS INC. cost of revenue for fiscal 2023 was $2.73M, a 400.56% increase from fiscal 2022.
- INMED PHARMACEUTICALS INC. cost of revenue for fiscal 2022 was $545.89K.
| Period end | Cost of Revenue 3 month | Cost of Revenue 3 month as first filed | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month | Cost of Revenue 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $635.99K 10-Q · filed 2026-02-11 | $1.35M 10-Q · filed 2026-02-11 | $2.08M derived: sum of 3 quarters · filed 2026-07-02 | $3.17M derived: sum of 4 quarters · filed 2026-07-02 | ||
| 2025-09-30 | $716.96K 10-Q · filed 2025-11-06 | $1.45M derived: sum of 2 quarters · filed 2026-07-02 | $2.53M derived: sum of 3 quarters · filed 2026-07-02 | $3.18M derived: sum of 4 quarters · filed 2026-07-02 | ||
| 2025-06-30 | $728.06K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $1.81M derived: sum of 2 quarters · filed 2026-07-02 | $2.46M derived: sum of 3 quarters · filed 2026-07-02 | $3.24M S-4 · filed 2026-07-02 | ||
| 2025-03-31 | $1.09M 10-Q · filed 2025-05-12 | $1.74M derived: sum of 2 quarters · filed 2026-02-11 | $2.51M 10-Q · filed 2025-05-12 | $3.32M derived: sum of 4 quarters · filed 2026-07-02 | ||
| 2024-12-31 | $650.81K 10-Q · filed 2026-02-11 | $1.42M 10-Q · filed 2026-02-11 | $2.24M derived: sum of 3 quarters · filed 2026-07-02 | $3.12M derived: sum of 4 quarters · filed 2026-07-02 | ||
| 2024-09-30 | $771.23K 10-Q · filed 2025-11-06 | $1.59M derived: sum of 2 quarters · filed 2026-07-02 | $2.47M derived: sum of 3 quarters · filed 2026-07-02 | $3.39M derived: sum of 4 quarters · filed 2026-07-02 | ||
| 2024-06-30 | $817.00K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $1.70M derived: sum of 2 quarters · filed 2026-07-02 | $2.62M derived: sum of 3 quarters · filed 2026-07-02 | $3.50M S-4 · filed 2026-07-02 | ||
| 2024-03-31 | $883.14K 10-Q · filed 2025-05-12 | $1.80M derived: sum of 2 quarters · filed 2025-05-12 | $2.68M 10-Q · filed 2025-05-12 | $4.00M derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $916.06K 10-Q · filed 2025-02-12 | $1.80M 10-Q · filed 2025-02-12 | $3.11M derived: sum of 3 quarters · filed 2025-02-12 | $3.96M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-09-30 | $880.62K 10-Q · filed 2024-11-14 | $787.69K 10-Q · filed 2023-11-14 | $2.20M derived: sum of 2 quarters · filed 2024-11-14 | $3.04M derived: sum of 3 quarters · filed 2024-11-14 | $3.38M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | $2.16M derived: sum of 2 quarters · filed 2024-09-30 | $2.50M derived: sum of 3 quarters · filed 2024-09-30 | $2.73M 10-K · filed 2024-09-30 | $2.42M 10-K · filed 2023-09-29 | |
| 2023-03-31 | $841.41K 10-Q · filed 2023-05-15 | $1.18M derived: sum of 2 quarters · filed 2023-05-15 | $1.42M 10-Q · filed 2023-05-15 | $1.68M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-12-31 | $338.62K 10-Q · filed 2023-02-17 | $573.65K 10-Q · filed 2023-02-17 | $838.70K derived: sum of 3 quarters · filed 2023-11-14 | $966.01K derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-09-30 | $235.03K 10-Q · filed 2023-11-14 | $500.08K derived: sum of 2 quarters · filed 2023-11-14 | $627.39K derived: sum of 3 quarters · filed 2023-11-14 | $780.92K derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $265.04K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | $392.35K derived: sum of 2 quarters · filed 2023-09-29 | $545.89K derived: sum of 3 quarters · filed 2023-09-29 | $545.89K 10-K · filed 2023-09-29 | ||
| 2022-03-31 | $127.31K 10-Q · filed 2023-05-15 | $280.85K derived: sum of 2 quarters · filed 2023-05-15 | $280.85K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $153.54K 10-Q · filed 2023-02-17 | $153.54K 10-Q · filed 2023-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |